HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial-Reference-Cited by-同舟云学术

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial

Published:2021-11 Issue:11 Volume:24 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Int AIDS Soc.

Author:

Parikh Urvi M.¹^ORCID,Penrose Kerri J.¹,Heaps Amy L.¹,Halvas Elias K.¹,Goetz B. Jay¹,Gordon Kelley C.¹,Hardesty Russell¹,Sethi Rahil¹,Schwarzmann William¹,Szydlo Daniel W.²,Husnik Marla J.²,Chandran Uma¹,Palanee‐Phillips Thesla³^ORCID,Baeten Jared M.⁴^ORCID,Mellors John W.¹,

Affiliation:

1. Department of Medicine, Division of Infectious Diseases University of Pittsburgh Pittsburgh Pennsylvania USA

2. Fred Hutchinson Cancer Research Center Seattle Washington USA

3. Wits Reproductive Health and HIV Institute Johannesburg South Africa

4. Departments of Global Health Medicine Epidemiology University of Washington Seattle Washington USA

Funder

Eunice Kennedy Shriver National Institute of Child Health and Human Development

National Institute of Mental Health

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25833

Reference36 articles.

1. What explains gender inequalities in HIV/AIDS prevalence in sub-Saharan Africa? Evidence from the demographic and health surveys

2. WHO. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. World Health Organization;2021.https://www.who.int/news/item/26‐01‐2021‐who‐recommends‐the‐dapivirine‐vaginal‐ring‐as‐a‐new‐choice‐for‐hiv‐prevention‐for‐women‐at‐substantial‐risk‐of‐hiv‐infection.

3. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

4. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women

5. European Medicines Agency. Dapivirine Vaginal Ring 25 mg H‐W‐2168: summary of product characteristics. European Medicines Agency;2020.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brief Report: HIV Drug Resistance Assessment Among Women Who Seroconverted During the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-01-01

2. HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic;Drugs;2023-12

3. Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction;Clinical Infectious Diseases;2022-11-08

4. Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials—The Ring Study and DREAM;Clinical Infectious Diseases;2022-10-03

5. Establishment and application of a method of tagged-amplicon deep sequencing for low-abundance drug resistance in HIV-1;Frontiers in Microbiology;2022-08-22